Released May 14, 2024, after the close
10-Q filed May 14, 2024, 44 days after period end · 0001140361-24-026010
Q1 2024 · 10-Q
Revenue$47.00K$47.00K — vs Q1 2023no prior Q4 2023 on file
Net Income-$6.65M-$6.65M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$1.23-$1.23 N/M vs Q1 2023no prior Q4 2023 on file
Gross Profit-$14,000N/M
Operating Income-$5,787,000N/M
Operating Cash Flow-$3,747,000N/M
Free Cash Flowderived-$3,848,000N/M
Margins · derived
Gross margin-29.8%
Operating margin-12312.8%
Net margin-14142.6%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $47.00K | $0.00 | — | — |
| Net Income | -$6.65M | -$5.42M | -$9.38M | -$18.52M |
| EPS Diluted | -$1.23 | -$1.06 | -$3.50 | -$0.67 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR